AR012427A1 - Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn - Google Patents
Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adnInfo
- Publication number
- AR012427A1 AR012427A1 ARP980101722A ARP980101722A AR012427A1 AR 012427 A1 AR012427 A1 AR 012427A1 AR P980101722 A ARP980101722 A AR P980101722A AR P980101722 A ARP980101722 A AR P980101722A AR 012427 A1 AR012427 A1 AR 012427A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- human
- modified
- tnf alpha
- molecule
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000008836 DNA modification Effects 0.000 title 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 9
- 102000057041 human TNF Human genes 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK41897 | 1997-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012427A1 true AR012427A1 (es) | 2000-10-18 |
Family
ID=8093298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101722A AR012427A1 (es) | 1997-04-15 | 1998-04-15 | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7118750B1 (https=) |
| EP (1) | EP0975668B1 (https=) |
| JP (1) | JP2001521386A (https=) |
| KR (1) | KR100522289B1 (https=) |
| CN (1) | CN1178955C (https=) |
| AR (1) | AR012427A1 (https=) |
| AT (1) | ATE326481T1 (https=) |
| AU (1) | AU743400B2 (https=) |
| BR (1) | BR9811462A (https=) |
| CA (1) | CA2289476A1 (https=) |
| CZ (1) | CZ9903657A3 (https=) |
| DE (1) | DE69834556T2 (https=) |
| DK (1) | DK0975668T3 (https=) |
| EE (1) | EE9900461A (https=) |
| ES (1) | ES2264569T3 (https=) |
| HR (1) | HRP980203B1 (https=) |
| HU (1) | HUP0001930A3 (https=) |
| IL (1) | IL132281A0 (https=) |
| NO (1) | NO995002L (https=) |
| NZ (1) | NZ337955A (https=) |
| PL (1) | PL194221B1 (https=) |
| RU (1) | RU2241715C2 (https=) |
| SI (1) | SI0975668T1 (https=) |
| SK (1) | SK285639B6 (https=) |
| TR (1) | TR199902562T2 (https=) |
| TW (1) | TW510921B (https=) |
| UA (1) | UA72440C2 (https=) |
| WO (1) | WO1998046642A1 (https=) |
| ZA (1) | ZA983148B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| JP2002538170A (ja) * | 1999-03-02 | 2002-11-12 | セントコール， インコーポレイテッド | 喘息の治療における抗−ＴＮＦα抗体 |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
| EP1296709A1 (en) * | 2000-06-21 | 2003-04-02 | Ferring BV | Solubilised protein vaccines |
| WO2003075951A2 (en) * | 2002-03-11 | 2003-09-18 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| AU2005220156B2 (en) | 2004-02-27 | 2011-06-02 | Vaxconsulting | Peptides of IL1 beta and TNF alpha and method of treatment using same |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| AU2008303582A1 (en) * | 2007-09-25 | 2009-04-02 | Intervet International B.V. | Vaccine for the treatment of osteoarthritis |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| US8703712B2 (en) | 2010-03-18 | 2014-04-22 | The Uab Research Foundation | Targeting cancer stem cells with DR5 agonists |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| AU2011340477A1 (en) | 2010-12-08 | 2013-06-20 | Neovacs | Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| CN102539778A (zh) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 |
| JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性Ａ−βに対する抗体を生成させるための能動免疫 |
| CN103376327A (zh) * | 2012-04-28 | 2013-10-30 | 通用电气公司 | 检测抗体或融合蛋白的浓度的方法 |
| WO2016179430A1 (en) | 2015-05-05 | 2016-11-10 | Rubicon Biotechnology Llc | Cancer immunotherapeutic |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3750056T2 (de) * | 1986-06-20 | 1995-04-06 | Dainippon Pharmaceutical Co | Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS. |
| DE3843534A1 (de) | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU634379B2 (en) | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2119089A1 (en) | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
-
1998
- 1998-04-15 CN CNB988042142A patent/CN1178955C/zh not_active Expired - Fee Related
- 1998-04-15 CA CA002289476A patent/CA2289476A1/en not_active Abandoned
- 1998-04-15 DK DK98916866T patent/DK0975668T3/da active
- 1998-04-15 AR ARP980101722A patent/AR012427A1/es unknown
- 1998-04-15 US US09/060,294 patent/US7118750B1/en not_active Expired - Fee Related
- 1998-04-15 RU RU99122686/13A patent/RU2241715C2/ru not_active IP Right Cessation
- 1998-04-15 ES ES98916866T patent/ES2264569T3/es not_active Expired - Lifetime
- 1998-04-15 BR BR9811462-0A patent/BR9811462A/pt not_active Application Discontinuation
- 1998-04-15 WO PCT/DK1998/000157 patent/WO1998046642A1/en not_active Ceased
- 1998-04-15 UA UA99116210A patent/UA72440C2/uk unknown
- 1998-04-15 HU HU0001930A patent/HUP0001930A3/hu unknown
- 1998-04-15 HR HR980203A patent/HRP980203B1/xx not_active IP Right Cessation
- 1998-04-15 AT AT98916866T patent/ATE326481T1/de not_active IP Right Cessation
- 1998-04-15 SK SK1409-99A patent/SK285639B6/sk unknown
- 1998-04-15 SI SI9830845T patent/SI0975668T1/sl unknown
- 1998-04-15 ZA ZA9803148A patent/ZA983148B/xx unknown
- 1998-04-15 JP JP54338798A patent/JP2001521386A/ja active Pending
- 1998-04-15 KR KR10-1999-7009504A patent/KR100522289B1/ko not_active Expired - Fee Related
- 1998-04-15 IL IL13228198A patent/IL132281A0/xx unknown
- 1998-04-15 CZ CZ19993657A patent/CZ9903657A3/cs unknown
- 1998-04-15 EE EEP199900461A patent/EE9900461A/xx unknown
- 1998-04-15 NZ NZ337955A patent/NZ337955A/xx unknown
- 1998-04-15 EP EP98916866A patent/EP0975668B1/en not_active Expired - Lifetime
- 1998-04-15 PL PL98336295A patent/PL194221B1/pl not_active IP Right Cessation
- 1998-04-15 AU AU70303/98A patent/AU743400B2/en not_active Ceased
- 1998-04-15 TR TR1999/02562T patent/TR199902562T2/xx unknown
- 1998-04-15 DE DE69834556T patent/DE69834556T2/de not_active Expired - Fee Related
- 1998-07-20 TW TW087111808A patent/TW510921B/zh not_active IP Right Cessation
-
1999
- 1999-10-14 NO NO995002A patent/NO995002L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012427A1 (es) | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn | |
| UY23762A1 (es) | Procedimiento de preparacion de lipopeptidos procedentes de actinoplanes sp. con efecto farmacologigo y sus usos | |
| CN104470943B (zh) | 新肽及其用途 | |
| AR062895A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| AR037456A1 (es) | Anticuerpos contra proteinas quimiotacticas monocitarias | |
| ES2573337T3 (es) | Apelina pegilada y usos de la misma | |
| UY28289A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores | |
| AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| AR033978A1 (es) | Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas | |
| CO6251321A2 (es) | Polipeptidos dominios variable s de anticuerpos y antagonistas | |
| ES2147553T3 (es) | Vectores virales recombinantes para la expresion en unas celulas musculares. | |
| Luo et al. | The role of monocyte/macrophage chemokines in pathogenesis of osteoarthritis: A review | |
| ES2730050T3 (es) | Interleuquina 38 truncada en el extremo terminal N | |
| UY23327A1 (es) | Proceso para la preparacion de muteina humana del factor de necrosis tumoral | |
| Shuai et al. | Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis | |
| DOP2020000192A (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina y usos de estos | |
| AR008387A1 (es) | Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas | |
| BR0314212A (pt) | Projeto de análogos de quimiocina para o tratamento de doenças humanas | |
| AR083546A1 (es) | Tratamiento de inflamacion gastrointestinal, soriasis y asma | |
| Cobos et al. | Peptides derived from hookworm anti-inflammatory proteins suppress inducible colitis in mice and inflammatory cytokine production by human cells | |
| Lee et al. | Clonorchis sinensis-derived protein attenuates inflammation and new bone formation in ankylosing spondylitis | |
| Yang et al. | The emerging spectrum of early life exposure-related inflammation and epigenetic therapy | |
| Ptitsyn | Invariant features of globin primary structure and coding of their secondary structure | |
| RU2017104284A (ru) | Выделенные полипептиды cd44 и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |